secwatch.observer — SEC 8-K summary
======================================

Issuer:     AYTU BIOPHARMA, INC (AYTU)
CIK:        0001385818
Form:       8-K
Filed at:   2023-02-21T23:59:59+00:00
Accession:  0001104659-23-023779
Event type: other_material
Sentiment:  negative
Materiality: 0.85
Item codes: 4.02
LLM model:  deepseek-v4-flash:cloud@v2

Aytu BioPharma restates Q1 FY2023 financials; warrant misclassification adds $5.6M liabilities
--------------------------------------------------------------------------------

- Audit committee concludes Sep 30, 2022 financials should be restated due to warrant misclassification as equity instead of liabilities.
- Restatement increases total liabilities by $5.6M, decreases equity by $3.4M, and reduces net loss by $2.2M.
- Material weakness in internal control over financial reporting identified; company working to remediate.
- Company expects to file 10-Q/A for Sep quarter and then 10-Q for Dec quarter as soon as practicable.
- Going forward, warrants will be classified as liabilities, which may adversely affect results of operations.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1385818/000110465923023779/0001104659-23-023779-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1385818/000110465923023779/tm237439d1_8k.htm
  HTML page:      https://secwatch.observer/filing/0001104659-23-023779

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer